IL6R and Recurrent upper respiratory tract infections: The frequency of most common adverse events like Upper respiratory tract infections, Urinary Tract Infections, hypercholesterolemia, and serious adverse events are similar to studies by Xie et al. and Xue et al. [28, 29] Though, cardiovascular disease is the main safety of concern in Anti-Interleukin-6 receptor inhibitors like Satralizumab and Tocilizumab as a result of an increase in cholesterol levels; recent trials [20] have shown no increase in the risk of cardiovascular disease [30].